| Literature DB >> 15598954 |
J F Smyth1, S Aamdal, A Awada, C Dittrich, F Caponigro, P Schöffski, M Gore, T Lesimple, N Djurasinovic, B Baron, M Ravic, P Fumoleau, C J A Punt.
Abstract
E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma.Entities:
Mesh：
Substances：
Year: 2005 PMID： 15598954 DOI： 10.1093/annonc/mdi016
Source DB: PubMed Journal: Ann Oncol ISSN： 0923-7534 Impact factor: 32.976